menu

CME: Tenosynovial Giant Cell Tumors: Mechanisms for Improving Patient Functionality and Outcomes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Tenosynovial Giant Cell Tumors: Mechanisms for Improving Patient Functionality and Outcomes

close
0.50 credits
30 Minutes
Tenosynovial Giant Cell Tumors: Mechanisms for Improving Patient Functionality and Outcomes
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Tenosynovial giant cell tumor (TGCT) is a potentially aggressive and debilitating disease characterized by overexpression of colony-stimulating factor-1 (CSF-1) in neoplastic synovial cells. Although rare, TGCT is nevertheless more common than previously appreciated, and the prevalence is relatively high given that many patients are young when the disease is diagnosed and will live with the disease for decades. Patients face a long and often difficult journey marked by multiple surgeries and surgical morbidity, decreases in physical function, and negative effects on quality of life and work productivity.

    There is a high unmet need for effective approaches to treating TGCT beyond surgery. The development of next-generation, potent inhibitors of the CSF-1/CSF-1 receptor axis have demonstrated dramatic and durable responses; in a randomized, phase 3 clinical trial, pexidartinib demonstrated a robust tumor response in patients with advanced TGCT, leading to the first-ever US Food & Drug Administration (FDA) approval of a treatment for this condition.

    This activity will review clinical advances and emerging research in TGCT, including diagnosis, treatment approaches, newly FDA-approved therapy, recent clinical trial data, and the relevance and integration of these new data into current practice.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify the signs and symptoms of tenosynovial giant cell tumors (TGCTs) to ensure prompt and accurate diagnosis
    • Examine when referral to centers of excellence is warranted for more complicated and unresectable cases of TGCT
    • Select treatment for TGCT based on available efficacy data, safety data, and current best practices for appropriate use and monitoring
    • Discuss treatment goals and preferences with patients with TGCT to ensure an informed and productive shared decision-making process
  • Target Audience

    This activity is intended for surgical, orthopedic, and medical oncologists; rheumatologists; sports medicine specialists; primary care providers; advanced practitioners; and other allied healthcare clinicians involved in the care of patients with TGCT.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. William D. Tap, MD, reported a financial interest/relationship or affiliation in the form of Advisor: Eli Lilly and Co; Daiichi Sankyo Co, Ltd; EMD Serono, Inc; Blueprint Medicines; Nanno Carrier; Deciphera Pharmaceuticals, LLC; Eisai Inc; Agios Pharmaceuticals, Inc; GlaxoSmithKline. Research grant: BioAtla; Immune Design; TRACON Pharmaceuticals, Inc; Plexxikon; Eli Lilly and Co; Daiichi Sankyo Company, Ltd; Blueprint Medicines; Deciphera Pharmaceuticals, LLC; Agios Pharmaceuticals, Inc. Received income in any amount from: Eli Lilly and Co; Daiichi Sankyo Company, Ltd; EMD Serono, Inc; Blueprint Medicines; Nanno Carrier; Deciphera Pharmaceuticals, LLC; Eisai Inc; Agios Pharmaceuticals, Inc; and GlaxoSmithKline. Ownership interest: Certis Oncology Solutions; and Atropos Therapeutics, Inc. Patents and royalties: Companion Diagnostics for CDK4 Inhibitors.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; and Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock, Merck.

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 02/19/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-20-003-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Commercial Support

    This activity is supported by an educational grant from Daiichi Sankyo, Inc.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Tenosynovial giant cell tumor (TGCT) is a potentially aggressive and debilitating disease characterized by overexpression of colony-stimulating factor-1 (CSF-1) in neoplastic synovial cells. Although rare, TGCT is nevertheless more common than previously appreciated, and the prevalence is relatively high given that many patients are young when the disease is diagnosed and will live with the disease for decades. Patients face a long and often difficult journey marked by multiple surgeries and surgical morbidity, decreases in physical function, and negative effects on quality of life and work productivity.

    There is a high unmet need for effective approaches to treating TGCT beyond surgery. The development of next-generation, potent inhibitors of the CSF-1/CSF-1 receptor axis have demonstrated dramatic and durable responses; in a randomized, phase 3 clinical trial, pexidartinib demonstrated a robust tumor response in patients with advanced TGCT, leading to the first-ever US Food & Drug Administration (FDA) approval of a treatment for this condition.

    This activity will review clinical advances and emerging research in TGCT, including diagnosis, treatment approaches, newly FDA-approved therapy, recent clinical trial data, and the relevance and integration of these new data into current practice.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify the signs and symptoms of tenosynovial giant cell tumors (TGCTs) to ensure prompt and accurate diagnosis
    • Examine when referral to centers of excellence is warranted for more complicated and unresectable cases of TGCT
    • Select treatment for TGCT based on available efficacy data, safety data, and current best practices for appropriate use and monitoring
    • Discuss treatment goals and preferences with patients with TGCT to ensure an informed and productive shared decision-making process
  • Target Audience

    This activity is intended for surgical, orthopedic, and medical oncologists; rheumatologists; sports medicine specialists; primary care providers; advanced practitioners; and other allied healthcare clinicians involved in the care of patients with TGCT.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. William D. Tap, MD, reported a financial interest/relationship or affiliation in the form of Advisor: Eli Lilly and Co; Daiichi Sankyo Co, Ltd; EMD Serono, Inc; Blueprint Medicines; Nanno Carrier; Deciphera Pharmaceuticals, LLC; Eisai Inc; Agios Pharmaceuticals, Inc; GlaxoSmithKline. Research grant: BioAtla; Immune Design; TRACON Pharmaceuticals, Inc; Plexxikon; Eli Lilly and Co; Daiichi Sankyo Company, Ltd; Blueprint Medicines; Deciphera Pharmaceuticals, LLC; Agios Pharmaceuticals, Inc. Received income in any amount from: Eli Lilly and Co; Daiichi Sankyo Company, Ltd; EMD Serono, Inc; Blueprint Medicines; Nanno Carrier; Deciphera Pharmaceuticals, LLC; Eisai Inc; Agios Pharmaceuticals, Inc; and GlaxoSmithKline. Ownership interest: Certis Oncology Solutions; and Atropos Therapeutics, Inc. Patents and royalties: Companion Diagnostics for CDK4 Inhibitors.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; and Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock, Merck.

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 02/19/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-20-003-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Commercial Support

    This activity is supported by an educational grant from Daiichi Sankyo, Inc.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 8/11/20